Phosphatidylinositol 3-kinase/Akt pathway regulates hepatic stellate cell apoptosis.
OBJECTIVE
To investigate the role of phosphatidylinositol 3-kinase (PI 3-K)/Akt signaling pathway in the balance of HSC activation and apoptosis in rat hepatic stellate cells (HSC).


METHODS
An activated HSC cell line was used in this study. LY 294002, the PI 3-K/Akt signal pathway blocker was used to investigate the molecular events on apoptosis in HSC and to interpret the role of this pathway in HSC apoptosis. Immunocytochemistry, Western blot and reverse transcription polymerase chain reaction (RT-PCR) analysis were applied to detect the expression of PI 3-K, and simultaneously phosphorylated-Akt (p-Akt) and total-Akt were determined by Western blot. The HSC apoptosis was examined by annexin-V/propidium iodide double-labelled flow cytometry and transmission electron microscopy.


RESULTS
The apoptosis rates in LY 294002 (30.82%+/-2.90%) and LY 294002+PDGF-BB (28.16%+/-2.58%) groups were significantly increased compared with those of control (9.02%+/-1.81%) and PDGF-BB (4.35%+/-1.18%). PDGF-BB augmented PI 3-K and p-Akt expression. LY 294002 significantly reduced the contents of PI 3-K and p-Akt. mRNA transcription evaluated by RT-PCR showed similar tendencies as protein expression.


CONCLUSIONS
Inhibition of PI 3-K/Akt signaling pathway induces apoptosis in HSC.
Wang
Yan
Y
Department of Gastroenterology, The Second Hospital of Hebei Medical University, The Hebei Institute of Gastroenterology, No. 215, Heping West Road, Shijiazhuang 050000, Hebei Province, China.
Jiang
Xiao-Yu
XY
Liu
Li
L
Jiang
Hui-Qing
HQ
D000818:Animals; D017209:Apoptosis / Q000502:physiology*; D000077214:Becaplermin; D002478:Cells, Cultured; D002867:Chromones / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D055166:Hepatic Stellate Cells / Q000166:cytology* / Q000187:drug effects / Q000201:enzymology / Q000502:physiology*; D009025:Morpholines / Q000494:pharmacology; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics / Q000502:physiology*; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics / Q000502:physiology*; D020574:Proto-Oncogene Proteins c-sis; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D015398:Signal Transduction / Q000502:physiology*
D002867:Chromones; D004791:Enzyme Inhibitors; D009025:Morpholines; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D012333:RNA, Messenger; D000077214:Becaplermin; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt
J Gastroenterol Hepatol. 2007 Jun;22 Suppl 1:S79-84
17567474
Blood. 2004 Jul 1;104(1):51-7
14996702
Transplant Proc. 2004 May;36(4):1163-5
15194403
Am J Obstet Gynecol. 2007 Feb;196(2):176.e1-5
17306671
Am J Pathol. 1997 Nov;151(5):1265-72
9358752
J Biol Chem. 2000 Dec 22;275(51):40561-7
11007794
J Hepatol. 2008 Jan;48(1):107-15
17998143
Semin Liver Dis. 2001 Aug;21(3):427-36
11586470
Exp Cell Res. 2001 Dec 10;271(2):201-13
11716532
Hepatology. 2002 Sep;36(3):582-91
12198650
Gastroenterology. 1997 Apr;112(4):1297-306
9098016
Physiol Rev. 2008 Jan;88(1):125-72
18195085
Semin Liver Dis. 2007 Nov;27(4):413-26
17979077
Lab Invest. 1991 Dec;65(6):644-53
1753710
Liver Int. 2007 May;27(4):434-9
17403182
J Biol Chem. 2002 Mar 29;277(13):11069-76
11796725
J Biol Chem. 2000 Jan 28;275(4):2247-50
10644669
Mol Biol Cell. 2000 Oct;11(10):3589-99
11029057
World J Gastroenterol. 2004 Oct 15;10(20):3001-5
15378782
J Cell Sci. 2003 Apr 15;116(Pt 8):1409-16
12640026